This page contains brief information about ponatinib hydrochloride and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Ponatinib hydrochloride is approved for use in adults to treat:
- Acute lymphoblastic leukemia that is Philadelphia chromosome positive and has the T315I mutation.
- Chronic myelogenous leukemia (CML) that has the T315I mutation. It is used in patients with chronic phase, accelerated phase, or blastic phase CML.
For these types of leukemia without the T315I mutation, ponatinib hydrochloride is used when other tyrosine kinase inhibitors cannot be used.
Ponatinib hydrochloride is being studied in the treatment of other types of cancer.
More About Ponatinib Hydrochloride
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Ponatinib Hydrochloride - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Ponatinib Hydrochloride - Check for trials from NCI's list of cancer clinical trials now accepting patients.